ClinicalTrials.Veeva

Menu

The Prevelence of IVS 1-6 (T-C) [HBB:c.92 +6 T-C] Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals

A

Assiut University

Status

Not yet enrolling

Conditions

Beta-Thalassemia

Treatments

Genetic: ARMS

Study type

Observational

Funder types

Other

Identifiers

NCT05370677
thalassemia mutation

Details and patient eligibility

About

    • To design an amplification-refractory mutation system (ARMS) for the DNA diagnosis of the IVS I-6 (T>C) mutation.
    • To detect the prevelence of the mutation among Assiut University Hospital patients.
    • Phenotype/genotype correlation of the mutation.

Full description

• The β-thalassaemias result from 300 gene mutations ( https://globin.bx.psu.edu ).

All of the mutations are regionally specific and the spectrum of mutations has now been determined for most at-risk populations(Old JM, 2007).

  • The strategy for identifying β-thalassaemia mutations is usually based on the knowledge of the common and rare mutations in the ethnic group of the individual being screened.(Old JM, 2007) .
  • In Mediterranean it represnts 8-15%
  • In Africa it represnts 3.5%
  • In Egyptians it represnts 13.6% ( https://globin.bx.psu.edu ).
  • The β globin gene mutation IVS I-6(T>C) is the First most common β globin gene mutation among Egyptians
  • (36.3%) according to ( Somaia El-Gawhary et al 2007 )
  • (27.66%) ( Ammar D. Elmezayen et al 2015 )
  • and the second most common mutation
  • (40%) according to ( El-shanshory M et al 2014)
  • (21.25%) ( Elhalfawy et al 2017) The molecular characterization of the globin gene mutation is necessary for definite diagnosis, genetic counseling, and to offer prenatal diagnosis. The amplification-refractory mutation system (ARMS) is a simple method for detecting any mutation involving single base changes or small deletions.
  • the DNA is analysed after amplification by PCR for Detection of point mutation IVS I-6(T>C) by Using primer pairs that only amplify individual alleles [ARMS] .

Enrollment

141 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • : β thalassemia (suspected & clinically diagnosed cases).

Exclusion criteria

  • : Iron deficiency anaemia, anaemia of chronic disease, types of haemolytic anaemias other than thalassemia, other types of thalassemia and Hb variants

Trial contacts and locations

0

Loading...

Central trial contact

Fatma Elzahraa Mohamed Abd Elrady

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems